Search - tctmd.com

Displaying 281 - 300 of 347

Sort: Relevancy | Date

News Daily News

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Michael O'Riordan

January 19, 2018

News Daily News

Exercise Study Hints at Volume, Intensity Levels Needed to Improve Cardiac Fitness in Middle Age

Shelley Wood

January 10, 2018

News Daily News

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

Michael O'Riordan

January 09, 2018

News Daily News

Diabetes Remission Possible With Significant Weight Loss: DiRECT

Michael O'Riordan

December 05, 2017

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

News Conference News AHA 2017

Novel Interatrial Shunt Succeeds in HF Hemodynamic Study: REDUCE LAP-HF I

Michael O'Riordan

November 21, 2017

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

News Conference News TCT 2017

Long-term Absorb BVS Data Continue to Disappoint

Michael O'Riordan

October 31, 2017

News Daily News

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Michael O'Riordan

October 26, 2017

News Daily News

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Michael O'Riordan

October 20, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Daily News

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Michael O'Riordan

October 17, 2017

News Daily News

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Michael O'Riordan

October 11, 2017

News Daily News

Asymptomatic Carotid Artery Stenosis: When to Screen and When to Intervene

Todd Neale

October 05, 2017

News Features

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Michael O'Riordan

September 13, 2017

News Conference News ESC 2017

Less Is More? Health Benefits of Fruits, Vegetables, and Legumes Seen at Lower Intake Levels

Michael O'Riordan

August 29, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Conference News ESC 2017

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

Shelley Wood

August 27, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Daily News

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Michael O'Riordan

August 14, 2017

Advertisement

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Exercise Study Hints at Volume, Intensity Levels Needed to Improve Cardiac Fitness in Middle Age

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

Diabetes Remission Possible With Significant Weight Loss: DiRECT

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Novel Interatrial Shunt Succeeds in HF Hemodynamic Study: REDUCE LAP-HF I

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Long-term Absorb BVS Data Continue to Disappoint

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Asymptomatic Carotid Artery Stenosis: When to Screen and When to Intervene

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Less Is More? Health Benefits of Fruits, Vegetables, and Legumes Seen at Lower Intake Levels

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content